HIV Pre-Exposure Prophylaxis: Scoping Review

Authors

DOI:

https://doi.org/10.33448/rsd-v12i11.43674

Keywords:

Human immunodeficiency; Pre-exposure prophylaxis; Pharmaceutical care; Pharmaceutical services; Pharmaceutical attention.

Abstract

Introduction: The lack of provision of HIV pre-exposure prophylaxis in medication dispensing units means that populations eligible for the use of prophylaxis are deprived of access, contributing to an increased risk of acquiring the HIV virus. Objective: To map potential strategies for pharmaceutical services and/or pharmaceutical care for Pre-exposure Prophylaxis to the Human Immunodeficiency Virus. Methodology: Scope review guided by the acronym PCC, where Participants: Pharmacists; Concept: Pre-exposure prophylaxis to the Human Immunodeficiency Virus; Context: Medium Complexity Health Care. Results: There are records that pharmaceutical services and/or pharmaceutical care for Pre-exposure Prophylaxis to the Human Immunodeficiency Virus reduce new cases of HIV, as does the offer of PrEP by pharmaceutical professionals. Conclusion: The findings show that pharmaceutical services and/or pharmaceutical care for Pre-exposure Prophylaxis to the Human Immunodeficiency Virus are robust.

References

Alohan, D.I., Evans, G., Sanchez, T., Harrington, K. R. V., Quamina, A., Young, H. N., & Crawford, N. D. (2023). Examining pharmacies' ability to increase pre-exposure prophylaxis access for black men who have sex with men in the United States. Journal of the American Pharmacists Association: JAPhA, 63(2), 547–554. https://doi.org/10.1016/j.japh.2022.11.004

Aragão, D. J., & Tavares, M. (2017). Como Preparar um Relato de caso Clínico. Cadernos UniFOA, 4(9):59–61. https://doi.org/10.47385/cadunifoa.v4.n9.939

Aromataris, E., & Munn, Z. (Editors). (2020). JBI Manual for Evidence Synthesis. JBI. https://synthesismanual.jbi.global. https://doi.org/10.46658/JBIMES-20-01

Bastos, J. L. D., & Duquia, R. P. (2007). Um dos delineamentos mais empregados em epidemiologia: estudo transversal. Scientia Medica, 17(4):229-232. Umdosdelineamentosmaisempregadosemepidemiologia (1).pdf

Bellman, R., Mohebbi, S., Nobahar, N., Parizher, J., & Apollonio, D. E. (2022). An observational survey assessing the extent of PrEP and PEP furnishing in San Francisco Bay Area pharmacies. Journal of the American Pharmacists Association: JAPhA, 62(1), 370–377.e3. https://doi.org/10.1016/j.japh.2021.08.001

Brasil. (2022). Ministério da Saúde. Conselho Nacional de Saúde. Resolução nº 674, de 06 de maio de 2022. Dispõe sobre a tipificação da pesquisa e a tramitação dos protocolos de pesquisa no Sistema CEP/CONEP. Brasília. Distrito Federal.

Brasil. (2020). Ministério da Saúde. Boletim Epidemiológico. HIV/Aids/2020. Número Especial. Brasília-DF. Dezembro/2020. http://www.aids.gov.br/pt-br/pub/2020/ boletim-epidemiologico-hivaids-2020

Brasil. (2020). Ministério da Saúde. Casos de Aids diminuem no Brasil. Boletim Epidemiológico sobre a Doença aponta queda na Taxa de Detecção de Aids no País desde 2012. Brasília-DF. http://www.aids.gov.br/pt-br/noticias/casos-de-aids-diminu em-no-brasil

Brasil. (2019). Ministério da Saúde. Relatório de Implantação PrEX HIV de janeiro a dezembro de 2018. Brasília. Distrito Federal. http://www.aids.gov.br/pt-br/pub/2019/relatorio-de-implantacao-da-profilaxia-pos-exposicao-prep-hiv

Brasil. (2021). Ministério da Saúde. Secretaria de Vigilância em Saúde. Protocolo Clínico e Diretrizes Terapêuticas para Profilaxia Pós-Exposição (PEP) de risco à infecção pelo HIV, IST e Hepatites Virais. Brasília. Distrito Federal. http://www.aids.gov.br/pt-br/pub/2015/protocolo-clinico-e-diretrize-terapeuticas-para-profilaxia-pos-exposicao-pep-de-risco

Brasil. (2021). Ministério da Saúde. Sistema de Controle Logístico de Medicamentos (SICLOM). Brasília. Distrito Federal. http://www. aids.gov.br/pt-br/gestores/sistemas-de-informacao/sistema-de-controle-logistico-de-medicamentos-siclom

Bunting, S. R., Feinstein, B. A., Bertram, C., Hazra, A., Sheth, N. K., & Garber, S. S. (2023). Effects of knowledge and implicit biases on pharmacy students' decision-making regarding pre-exposure prophylaxis for HIV prevention: A vignette-based experimental study. Currents in pharmacy teaching & learning, 15(2), 139–148. https://doi.org/10.1016/j.cptl.2023.02.019

Burns, C. M., Endres, K., Derrick, C., Cooper, A., Fabel, P., Okeke, N. L., Ahuja, D., Corneli, A., & McKellar, M. S. (2023). A survey of South Carolina pharmacists' readiness to prescribe human immunodeficiency virus pre-exposure prophylaxis. Journal of the American College of Clinical Pharmacy, JACCP, 6(4), 329-338. https://doi.org/10.1002/jac5.1773

Cernasev, A., Melton, T. C., Jasmin, H., & Barenie, R. E. (2023). A Qualitative Systematic Literature Review of the Role of U.S. Pharmacists in Prescribing Pre-Exposure Prophylaxis (PrEP). Pharmacy, 11(1), 9. https://doi.org/10.3390/pharmacy11010009

Cernasev, A., Barénie, R. E., Wofford, B. R., Dourado, J., & Walker, C. (2023). Empowering Tennessee Pharmacists to Initiate PrEP Using Collaborative Pharmacy Practice Agreements. Clin. Pratique, 13, 280- 287. https://doi.org/10.3390/clinpract13010025

Chaves, J. C., Lo Prete, A. C., Soler, O. & Azevedo-Ribeiro, C. H. M. (2021). Intervenções farmacêuticas e seus desfechos em portadores de HIV/AIDS em atendimento de média complexidade. Revista Eletrônica Acervo Saúde, 13(4), 1-14. https://doi.org/10.25248/REAS.e43 90.2021

Conselho Nacional de Secretarias Municipais de Saúde (CONASEMS). (2023). Instrumento de referência dos serviços farmacêuticos na Atenção Básica. Chaves, E. S., Hamida, H. M., Junqueira, M. (Coord.). 68p. Brasília. Distrito Federal.

Cordeiro, L., & Baldini, S.C. (2020). Revisão de escopo: potencialidades para a síntese de metodologias utilizadas em pesquisa primária qualitativa. BIS. Boletim do Instituto de Saúde, 20(2), 3743. docs.bvsalud.org/biblioref/2019/10/1021863/bis-v20n2-sintese-de-evidencias-qualitativas-37-43.pdf

Crawford, N. D., Josma, D., Morris, J., Hopkins, R., & Young, H. N. (2020). Pharmacy-based pre-exposure prophylaxis support among pharmacists and men who have sex with men. Journal of the American Pharmacists Association: JAPhA, 60(4), 602-608. https://doi.org/10.1016/j.japh.2019.12.003

Farmer, E. K., Koren, D. E., Cha, A., Grossman, K., & Cates, D. W. (2019). The Pharmacist's Expanding Role in HIV Pre-Exposure Prophylaxis. AIDS patient care and STDs, 33(5), 207-213. https://doi.org/10.1089/apc.2018.0294

Greenwell, K., Fugit, R., Nicholson, L., & Wright, J. A. (2023). Retrospective Comparison of HIV Pre-exposure Prophylaxis (PrEP) Outcomes Between a Pharmacist-led Telehealth Clinic and In-person Clinic in a Veteran Population. AIDS Behav. https://doi.org/10.1007/s10461-023-04084-2

Havens, J. P., Scarsi, K. K., Sayles, H., Klepser, D. G., Swindells, S., & Bares, S. H. (2019). Acceptability and feasibility of a pharmacist-led HIV pre-exposure prophylaxis (PrEP) program in the Midwestern United States. Open forum infectious diseases, 6(10), ofz365. https://doi.org/10.1093/ofid/ofz365

Khosropour, C. M., Backus, K. V., Means, A. R., Beauchamps, L., Johnson, K., Golden, M. R., & Mena, L. (2020). A Pharmacist-Led, Same-Day, HIV Pre-Exposure Prophylaxis Initiation Program to Increase PrEP Uptake and Decrease Time to PrEP Initiation. AIDS patient care and STDs, 34(1), 1-6. https://doi.org/10.1089/apc.2019.0235

Koester, K. A., Saberi, P., Fuller, S. M., Arnold, E. A., & Steward, W. T. (2020). Attitudes about community pharmacy access to HIV prevention medications in California. Journal of the American Pharmacists Association: JAPhA, 60(6), e179-e183. https://doi.org/10.1016/j.japh.2020.06.005

Li, D. H., Benbow, N., Keiser, B., Mongrella, M., Ortiz, K., Villamar, J., Gallo, C., Deskins, J. S., Xavier Hall, C. D., Miller, C., Mustanski, B., & Smith, J. D. (2022). Determinants of Implementation for HIV Pre-exposure Prophylaxis Based on an Updated Consolidated Framework for Implementation Research: A Systematic Review. Journal of acquired immune deficiency syndromes (1999), 90(S1), S235-S246. https://doi.org/10.1097/QAI.0000000000002984

Lopez, M. I., Cocohoba, J., Cohen, S. E., Trainor, N., Levy, M. M., & Dong, B. J. (2020). Implementation of pre-exposure prophylaxis at a community pharmacy through a collaborative practice agreement with San Francisco Department of Public Health. Journal of the American Pharmacists Association: JAPhA, 60(1), 138-144. https://doi.org/10.1016/j.japh.2019.06.021

McCree, D. H., Byrd, K. K., Johnston, M., Gaines, M., & Weidle, P. J. (2020). Roles for Pharmacists in the "Ending the HIV Epidemic: A Plan for America" Initiative. Public health reports (Washington, D.C.: 1974), 135(5), 547–554. https://doi.org/10.1177/0033354920941184

Meyerson, B. E., Dinh, P. C., Agley, J. D., Hill, B. J., Motley, D. N., Carter, G. A., Jayawardene, W., & Ryder, P. T. (2019). Predicting Pharmacist Dispensing Practices and Comfort Related to Pre-exposure Prophylaxis for HIV Prevention (PrEP). AIDS Behav, 23, 1925-1938. https://doi.org/10.1007/s10461-018-02383-7

Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7), e1000097. 10.1371/journal.pmed1000097

Moraes Filho, D. S., Martins, L. H. C., Costa, R. N., Queiroz, L. M. D., Passos, M. M. B., & Soler, O. (2022). Pharmacists’ perception of their technical-assistance and managerial-technical functions in private community pharmacies. Research, Society and Development, 11(2), e33611225743. https://doi.org/10.33448/rsd-v11i2.25743

Murad, M. H., Asi, N., Alsawas, M., & Alahdab, F. (2016). New evidence pyramid. Evid Based Med, 21(4), 125-127. 10.1136/ebmed-2016-110401. untitled (bmj.com)

Mussi, R. F. F., Flores, F. F., & Almeida, C. B. (2021). Pressupostos para a elaboração de relato de experiência como conhecimento científico. Práxis Educacional, Vitória da Conquista, 17(48), 60-77. 10.22481/praxisedu.v17i48.9010.

Nakambale, H. N., Roche, S. D., Mogere, P., Omollo, V., Kuo, A. P., Stergachis, A., Baeten, J. M., Bukusi, E., Ngure, K., Mugambi, M. L., & Ortblad, K. F. (2023). Barriers to and strategies for early implementation of pharmacy-delivered HIV PrEP services in Kenya: An analysis of routine data. Frontiers in reproductive health, 5, 1023568. https://doi.org/10.3389/frph.2023.1023568

Okoro, O., & Hillman, L. (2018). HIV pre-exposure prophylaxis: Exploring the potential for expanding the role of pharmacists in public health. Journal of the American Pharmacists Association: JAPhA, 58(4), 412-420.e3. https://doi.org/10.1016/j.japh.2018.04.007

Oliveira, M. A., Vellarde, G. C., & Sá, R. A. M. (2015). Entendendo a pesquisa clínica III: estudos de coorte. FEMINA. 43(3), 105-110. a5116.pdf (bvs.br)

Oliveira, T. C., Vieira, H. K. S., Elmescany, S. B., Gonçalves, S. T., Santos, V. R. C., & Soler, O. (2021). Interventions applied to the prescription, use and administration of medications as strategic factors for patient safety: systematic review. Research, Society and Development, 10(17), e195101724601. https://doi.org/10.33448/rsd-v10i17.24601

Peters, M. D. J. et al. (2020). Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth;18(10):2119-26. https://doi.org/10.11124/JBIES-20-00167

Porto, F., & Gurgel, J. L. (2018). Sugestão de roteiro para avaliação de um artigo científico. Rev Bras Ciênc Esporte, 40(2), 111-116. https://doi.org/10.1016/j.rbce.2017.12.002

Przybyla, S. M., Parks, K., Bleasdale, J., Sawyer, J., & Morse, D. (2019). Awareness, knowledge, and attitudes towards human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) among pharmacy students. Currents in pharmacy teaching & learning, 11(4), 352-360. https://doi.org/10.1016/j.cptl.2019.01.011

Shea, B. J., Grimshaw, J. M., Wells, G. A., Boers, M., Andersson, N., Hamel, C., Porter, A. C., Tugwell, P., Moher, D., & Bouter, L. M. (2007). Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 15(7), 10.

Thiese, M. S. (2014). Observational and interventional study design types; an overview. Biochem Med (Zagreb), 24, 199-210. Observational and interventional study design types; an overview - Biochemia Medica (biochemia-medica.com)

Tricco, A. C. et al. (2018). Prisma Extension for Scoping Reviews Prisma-ScR): checklist and explanation. Ann Intern Med, 169(7), 467-73. https://doi.org/10.7326/M18-0850

Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D., Horsley, T., Weeks, L., Hempel, S. et al. (2018). Prisma extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med.,169(7), 467-473. 10.7326/M18-0850.

Tung, E. L., Thomas, A., Eichner, A., & Shalit, P. (2018). Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. Sexual health, 15(6), 556-561. https://doi.org/10.1071/SH18084

Wilby, K. J., & Smith, A. J. (2020). A Narrative Review of Continuing Professional Development Needs for Pharmacists with Respect to Pre-exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV). Pharmacy 8(2), 84. https://doi.org/10.3390/pharmacy8020084

Zhao, A., Dangerfield, D. T., Nunn, A., Patel, R., Farley, J. E., Ugoji, C. C., & Dean, L. T. (2022). Pharmacy-Based Interventions to Increase Use of HIV Pre-exposure Prophylaxis in the United States: A Scoping Review. AIDS and behavior, 26(5), 1377-1392. https://doi.org/10.1007/s10461-021-03494-4

Published

23/10/2023

How to Cite

MONTEIRO, H. da S. .; QUEIROZ, L. M. D. de .; SOLER, O. . HIV Pre-Exposure Prophylaxis: Scoping Review. Research, Society and Development, [S. l.], v. 12, n. 11, p. e36121143674, 2023. DOI: 10.33448/rsd-v12i11.43674. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/43674. Acesso em: 16 may. 2024.

Issue

Section

Health Sciences